tiprankstipranks
Advertisement
Advertisement

Novo Nordisk Advances Amycretin to Phase 3 for Weight Management

Story Highlights
  • Novo Nordisk plans to advance amycretin into phase 3 for weight management.
  • Phase 3 trials for amycretin are set to begin in early 2026, enhancing Novo Nordisk’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Novo Nordisk Advances Amycretin to Phase 3 for Weight Management

Elevate Your Investing Strategy:

Novo Nordisk ( (NVO) ) just unveiled an update.

On June 12, 2025, Novo Nordisk announced plans to advance its subcutaneous and oral amycretin into phase 3 clinical development for weight management. This decision follows positive feedback from regulatory authorities after phase 2 trials. The move signifies a significant step forward for the company in addressing overweight and obesity issues, with phase 3 trials set to begin in the first quarter of 2026. Amycretin, a long-acting GLP-1 and amylin receptor agonist, is designed to provide effective treatment for adults with overweight, obesity, and type 2 diabetes, potentially enhancing Novo Nordisk’s position in the healthcare market.

The most recent analyst rating on (NVO) stock is a Sell with a $82.50 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.

Novo Nordisk’s strong financial performance, evidenced by impressive profitability and cash flow, is the primary driver of its stock score. The earnings call further supports this with robust sales and strategic growth initiatives, despite challenges in the U.S. market. Technical analysis indicates short-term momentum, although long-term trends suggest caution. Valuation metrics point to potential overvaluation, slightly tempering the overall score.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly diabetes, through scientific breakthroughs and expanding access to medicines. Novo Nordisk employs approximately 77,400 people in 80 countries and markets its products in around 170 countries. Its B shares are listed on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange.

Average Trading Volume: 10,006,650

Technical Sentiment Signal: Buy

Current Market Cap: $355.2B

Learn more about NVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1